Pain-and-nausea signaling fragment (Substance P [1-6])
A lab-made snippet of the body's natural pain-and-nausea messenger, substance P, used to study how this messenger binds its receptor, a target for anti-nausea drugs like aprepitant. Used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Substance P [1-6] (sequence RPKPQQ) is a synthetic hexapeptide corresponding to the first six amino acids of substance P, the 11-residue neuropeptide that the body uses to signal pain, nausea, and inflammation. The full-length parent peptide — first detected in 1931 by Ulf von Euler and John Gaddum as a bioactive substance in intestinal and brain extracts, and fully sequenced from bovine hypothalamus in 1971 — is the founding mammalian ligand for the neurokinin 1 receptor (NK1R). Substance P [1-6] retains only the N-terminal half of that parent sequence and is used in research to probe what the N-terminal region of substance P contributes to receptor binding, selectivity, and activity — and to provide a well-defined structural reference for NK1R antagonist development.
History
Substance P was first characterized in 1931 when von Euler and Gaddum isolated an unidentified factor from equine brain and intestine that caused smooth muscle contraction and hypotension — properties that could not be blocked by atropine. Its complete amino acid sequence (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met with a C-terminal amide) was determined in 1971 from bovine hypothalamus. The molecular blueprint of the precursor protein was decoded in the early 1980s when Nawa and Nakanishi showed that two forms of preprotachykinin A (PPT-A) mRNA arise from a single gene through alternative splicing. In 1986, Kawaguchi and colleagues reported the sequence of cloned cDNA for the rat substance P precursor and identified a third PPT-A variant, establishing that alternative splicing of the preprotachykinin gene generates multiple distinct precursor forms across species (Kawaguchi and colleagues, Biochemical and Biophysical Research Communications, 1986). Truncated N-terminal fragments such as SP [1-6] became laboratory tools as structure-activity studies in the 1980s and 1990s systematically mapped which portions of the parent sequence were required for receptor selectivity, receptor activation, and the distinct pharmacology observed with short SP fragments.
What it does
Substance P [1-6] presents the proline- and basic-residue-rich N-terminal segment of the parent peptide in isolation. In the full-length substance P molecule, the C-terminal hexapeptide (residues 7–11, Phe-Phe-Gly-Leu-Met-NH₂) is the primary pharmacophore that anchors the peptide in the NK1R orthosteric pocket and drives receptor activation; that C-terminal amide and aromatic cluster are absent from SP [1-6]. The N-terminal region, by contrast, is structurally flexible and solvent-exposed when the parent peptide is bound to NK1R, and contributes to receptor subtype selectivity rather than direct activation. Consistent with this architecture, pharmacological studies of N-terminal SP fragments show that they do not independently activate NK1R in the way full-length SP does, and their biological effects in vivo are mediated through mechanisms distinct from classical NK1R agonism. The fragment is therefore used experimentally as an N-terminal reference compound — to compare against C-terminal fragments, full-length SP, and modified analogs — in SAR (structure-activity relationship) studies aimed at understanding NK1R and at developing antagonists. The NK1R antagonist aprepitant, approved for chemotherapy-induced nausea and vomiting, emerged from decades of SP-based SAR work in which fragments like SP [1-6] served as structural benchmarks.
Evidence
- Human: No human trials have been conducted with Substance P [1-6] as an investigational agent. Its use is confined to basic research.
- Animal: Preclinical studies on N-terminal SP fragments, including behavioral and receptor-binding assays, have established that these fragments do not replicate the NK1R-mediated nociceptive and emetic effects of full-length SP, and that their in vivo effects are naloxone-sensitive in some models — pointing to opioid-receptor-mediated rather than NK1R-mediated mechanisms.
- In vitro: SP [1-6] is used as a reference compound in competition binding assays and receptor activation studies at the neurokinin 1 receptor; its weak displacement of radiolabeled SP from NK1R binding sites is contrasted with the potent, C-terminal-dependent binding seen with full-length SP and C-terminal fragments.
Known effects
- NK1R research reference — Used as a structural control in SAR experiments to define the N-terminal boundary of NK1R pharmacophore requirements; preclinical only
- Selectivity probe — The N-terminal proline-rich sequence (including Pro at position 4 and Pro at position 2) contributes to tachykinin receptor subtype selectivity; preclinical/mechanistic
- Distinct fragment pharmacology — N-terminal SP fragments act via mechanisms separate from NK1R agonism; mechanistic only
Regulatory status
- US: No FDA approval; not an approved drug or biologic. Research use only.
- EU: No EMA approval. Research use only.
- ClinicalTrials.gov: No registered clinical trials for Substance P [1-6].
Mechanism
Substance P [1-6] covers residues 1–6 of the parent 11-residue tachykinin sequence. In the full-length peptide, the conserved tachykinin C-terminal motif (Phe-X-Gly-Leu-Met-NH₂) is anchored within the transmembrane orthosteric pocket of NK1R; upon binding, the receptor couples to Gαq/11 (activating phospholipase C, generating IP3 and DAG, and elevating intracellular calcium), to Gαs (stimulating cAMP via adenylyl cyclase), and to downstream effectors including NF-κB and proinflammatory cytokines (Douglas and colleagues, Annals of the New York Academy of Sciences, 2011). NK1R also undergoes rapid agonist-driven internalization followed by recycling to the membrane surface. SP [1-6], which ends at Gln⁶ and carries no C-terminal amide, does not present the phenylalanine-rich anchor sequence required for this orthosteric engagement, explaining its lack of classical NK1R agonist activity. Residues in the N-terminal segment — particularly the prolines at positions 2 and 4 — are instead thought to contribute conformational rigidity and receptor subtype selectivity information, as supported by studies showing that tachykinins bearing a proline at position 4 (such as physalaemin) display NK1 selectivity. In the broader context of substance P biology, Schank and colleagues (International Review of Neurobiology, 2017) reviewed how the SP–NK1R axis intersects with stress neurocircuitry, noting parallels to corticotropin-releasing factor (CRF) systems in anxiety, addiction, and affective behavior — underscoring why structural tools that dissect the N-terminal and C-terminal contributions of SP remain relevant to receptor-targeted drug development.
Related peptides
- Substance P — the full 11-residue parent neuropeptide (RPKPQQFFGLM-NH₂) of which SP [1-6] is the N-terminal hexapeptide fragment; the prototypical endogenous NK1R agonist and founding tachykinin
- Substance P [1-7] — a related N-terminal fragment (one residue longer) with documented pharmacology acting through a receptor site distinct from NK1R and from opioid receptors; studied as an endogenous modulator of SP actions in the CNS
- Substance P [4-11] — a C-terminal-containing fragment that retains NK1R binding capacity, in contrast to the N-terminal-only SP [1-6]
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could this short fragment latch onto the pain receptor but only turn it on partway, rather than blocking it completely?
If true, this fragment could dampen pain and nausea signals without switching them off entirely, which might reduce side effects compared to current drugs that fully block the receptor. Patients with chronic pain or chemotherapy-induced nausea could potentially benefit from a more nuanced approach to controlling these signals.
If this fragment were chemically looped into a ring, would it bind the pain receptor more tightly and survive longer in the body?
Short peptides like this one are usually broken down within minutes in the bloodstream, limiting their medical use. Locking the fragment into a ring shape could extend its lifetime and strengthen its grip on the target receptor, potentially making it a real drug candidate for pain, nausea, or stress conditions rather than just a laboratory tool.
Does the double-proline backbone of this fragment help it find only the NK1 receptor and avoid binding to its cousins?
A fragment that sticks to only one of the three neurokinin receptors would be a cleaner drug starting point, potentially reducing side effects like airway constriction that come from hitting the wrong family member. This matters for anyone developing antiemetics or pain medicines with fewer respiratory risks.
If this short fragment occupies the NK1 receptor on immune cells, could it reduce the receptor activity that the HIV virus takes advantage of?
HIV thrives partly by hijacking normal immune cell signaling. If a naturally derived fragment could quietly block that pathway, it might slow viral replication through a mechanism completely different from existing HIV drugs, which could be valuable for patients who have developed drug resistance or who need treatment options for the brain compartment where standard antiretrovirals struggle to reach.
Are the two glutamine residues at the end of this fragment essential for giving it the right three-dimensional shape to bind NK1R?
If removing just one glutamine from the end of this fragment breaks its binding much more than expected, that finding would tell chemists exactly where to focus when designing improved, longer-lasting versions of the fragment. Better designed fragments could become more effective drugs for pain or nausea with fewer doses needed.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8431396484375 | boltz-2 |
| ranking score | 0.7422506809234619 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10632,
sequence = {RPKPQQ},
target = {tacr1},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}